Эффективность и переносимость парентерального применения железа у гемодиализных пациентов, сравнение препаратов
жүктеу/скачать 418,5 Kb.
|
effectivnost-parenteralnogo-priema
| Литература
1 Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander? Arch Intern Med 2003; 163:1400-4. 2 Silverberg D, Blum M, Agbaria Z, et al. Intravenous Iron for the treatment of predialysis anaemia. Kidney Int 1999; 69(Suppl.): S79-85. 3 Valderrabano F, Horl W, Macdougall I, et al. Pre-dialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18: 89-100. 4 Bhandari S, Brownjohn A, Turney J. Effective utilization of erythropoietin with intravenous iron therapy. J Clin Pharm Ther 1998; 23: 73-8. 5 Bhandari S, Norfolk D, Brownjohn A, Turney J. Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. Am J Kidney Dis 1997; 30: 814-21. 6 Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-6. 7 Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004; 76: 74-8. 8 Coyne DW, Adkinson NF, Nissenson AR, ef al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217-24. 9 Fletes R, Lazarus JM, Gage J, Chertow M. Suspected iron dextran-related adverse events in haemodialysis patients. Am J Kidney Dis 2001; 37: 743-9. 10 McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products. Am J Nephrol 2000; 20: 455-62. 11 Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatric Gastroenterol Nutr 2002; 34: 286-90. 12 Case G. Maintaining iron balance with total-dose infusion of intravenous iron dextran. ANNA J 1998; 25: 65-8. 13 Chertow GM, Mason PD, Vaage-Nilsen 0, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19: 1571-5. 14 Venofer Package Insert. American Regent Laboratories, Inc.: Shirley, NY, 2000. 15 Macdougall I, Bailie G, Ridchardson D, Tanner J, Gagnon SP. Worldwide safety profile of iron sucrose injection (Venofer): analysis of 1,044,477 patients from 1992 to 2001. J Am Soc Nephrol 2001; 12:333A (abstract). 16 Medicines and Healthcare Products Regulatory Agency (MHRA). Yellow Card Database, UK. Accessed at http://www.yellowcard.gov.uk (last accessed 29/01/07). 17 Fishbane S, Kowalski E. The comparative safety of intravenous iron dextran, iron sacchrate and sodium ferric gluconate. Semin Dial 2000; 13: 381-4. 18 Yee J, Besarab A. Iron sucrose the oldest iron therapy becomes new. Am J Kidney Dis 2002; 40: 1111-21. 19 Charytan C, Leven N, Al-Saloum M, et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysisassociated anemia. North American Clinical Trial. Am J Kidney Dis 2001; 37:300-7. 20 Fishbane S, Ungureanu V, Maesak JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-34. 21 Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran. North American Clinical Trial. Am J Kidney Dis 2000; 36: 88-97. 22 Eichbaum Q, Foran S, Dzik S. Is iron gluconate really safer than iron dextran? Blood 2003; 101: 3756-7. 23 Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19; (Suppl. 2):i i l - 4 7 . жүктеу/скачать 418,5 Kb. Достарыңызбен бөлісу:
|